Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Kluisbergen – page 82

2 297 clinical trials in Kluisbergen, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Kluisbergen at a glance
2 297
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 297 trials in Kluisbergen

Open in trial search

HIV infection

Not yet recruiting

Study of Baricitinib and Sirolimus to Maintain HIV Infection Control After Antiretroviral Treatment Interruption in Adults

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Baricitinib
  • Sponsor:ANRS Maladies Infectieuses Emergentes

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Acne

Not yet recruiting

Low-dose isotretinoin compared with drug combination for treating acne in adult women: a two‑step randomized trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Adapalene
  • Sponsor:Assistance Publique Hopitaux De Paris

Acute myeloid leukaemia

Not yet recruiting

Study of quizartinib‑based drug combination on measurable residual disease in adults 18‑60 with acute myeloid leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azacitidine
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

C3 glomerulopathy

Not yet recruiting

Pegcetacoplan to Prevent Recurrence of C3 Glomerulopathy or Primary Immune‑Complex MPGN in Adolescent and Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Study on the Safety and Immune Response of GBS-NN/NN2 and Tdap Vaccines in Preventing Group B Strep Infection in Healthy Women Aged 18-49

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:GBS-NN
  • Sponsor:Minervax ApS

Secondary immunodeficiency

Not yet recruiting

Study of Human Normal Immunoglobulin in Adults with Secondary Immune Deficiency after CAR T‑cell or T‑cell Redirecting Therapy for Hematologic Malignancies

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Thrombosis prophylaxis

Not yet recruiting

Randomized trial of standard vs high-dose enoxaparin and sodium chloride for preventing clots in critically ill ICU patients at high risk of thrombosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Hopital Erasme

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Kluisbergen

What the registry says about research in the country

01 Respiratory Virus Research

Comprehensive studies focusing on respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) prevention in older adults. Researchers are evaluating innovative vaccine approaches for these common respiratory pathogens.

  • RSV Vaccine Development
  • Co-administration Studies
  • Elderly Population Protection

Multiple trials are examining vaccine effectiveness and immune responses in adults over 60 years of age.

02 Influenza Prevention

Research examining a novel influenza vaccine in both younger and older adult populations. The studies focus on safety assessment and immune system response evaluation.

  • Vaccine Safety Analysis
  • Immune Response Measurement
  • Cross-age Group Studies

Trials aim to establish optimal dosing while ensuring robust protection against influenza.

03 Urinary Health Initiatives

Clinical research targeting urinary tract infections (UTI), with particular attention to prevention through vaccination. Studies include both male and female participants aged 18-64.

  • UTI Prevention
  • E. coli-specific Protection
  • Vaccine Safety Evaluation

The research focuses on developing preventive measures against common bacterial infections.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.